ABBV · News · 20260903N
Acquisition / Partnership / Divestiture
AbbVie Inc. · 2026-09-03 · Importance 71 · Surprise 60 · In source text
AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics on September 3, 2026. The transaction adds zumilokibart, a late-stage half-life-extended IL-13 antibody for atopic dermatitis, and APG273, a long-acting IL-13/TSLP combination for asthma. Third-party reports said the acquisition is expected to dilute adjusted diluted EPS in 2026 and 2027, with accretion anticipated beginning in 2032. The deal expands AbbVie’s immunology pipeline and supports longer-term growth as existing products approach loss of exclusivity.
Key facts
- AbbVie completed its acquisition of Apogee Therapeutics for $10.9 billion (reported also as $11B in some outlets). source
- AbbVie completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -8.1% | AbbVie completed its acquisition of Apogee Therapeutics for $10.9 billion (reported also as $11B in some outlets). |
| assets | positive | realized | — | AbbVie completed its acquisition of Apogee Therapeutics for $10.9 billion (reported also as $11B in some outlets). |